Nasdaq · Healthcare

CAPRICOR THERAPEUTICS, INC. (CAPR)

As-reported financials and recent SEC filings for CAPRICOR THERAPEUTICS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

Net income

$-105.0M

Net margin

—

Diluted EPS

$-2.26

ROE

-34.4%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$0	$22.3M	$25.2M	$2.6M	$244,898
Gross profit	—	—	—	—	—
Operating income	$-108.1M	$-42.6M	$-24.1M	$-29.7M	$-20.9M
Net income	$-105.0M	$-40.5M	$-22.3M	$-29.0M	$-20.0M
Diluted EPS	$-2.26	$-1.15	$-0.83	$-1.18	$-0.87

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-06-29

42026-06-29

8-K2026-06-26

42026-06-24

42026-06-24

8-K2026-06-08

42026-05-28

32026-05-28

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on CAPR

Search CAPRICOR THERAPEUTICS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.